This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Analysts' Actions: AIZ GLW JNJ LLY MRK


Assurant (AIZ - Get Report) was upgraded at Bank of America/Merrill Lynch to neutral. $60 price target. Company is seeing a pricing overhang easing in Florida, BofA/Merrill said.

Chesapeake Energy (CHK) was downgraded at Stifel Nicolaus to hold from buy. Valuation call, given low expectations for production growth, Stifel Nicolaus said.

Emcor (EME) was upgraded at DA Davidson to buy from neutral. Company is leveraged to a recovering nonresidential construction environment, DA Davidson said.

Corning (GLW - Get Report) downgraded at Piper Jaffray to neutral from overweight. $14 price target. Company lacks exposure to new product cycle in display.

[Read: <a target="blank" data-add-tracking="true" href=""><em>The Deal: Lloyds Offloads Remaining Australian Assets</em></a>]

JB Hunt (JBHT) was upgraded at Bank of America/Merrill Lynch to buy from neutral. $81 price target. Company offers a strong secular growth story, BofA/Merrill said.

Johnson & Johnson (JNJ - Get Report) was upgraded at Goldman Sachs to neutral from sell. Pharma outlook is improving, Goldman said. $95 price target.

Life Technologies (LIFE) was downgraded to hold at TheStreet Ratings.

Eli Lilly (LLY - Get Report) was downgraded at Jefferies to underperform from buy. Estimates were also lowered, given worsening business environment and disappointing R&D productivity, Jefferies said. $40 price target.

L Brands (LTD) was downgraded at Credit Suisse to neutral from outperform. $64 price target. Comp weakness persists and inventories are building, Credit Suisse said.

Merck (MRK - Get Report) was downgraded at Jefferies to hold from buy. Estimates were also decreased on weak business environment and unimpressive cost-cutting initiatives, Jefferies said. $50 price target.

[Read: <a target="blank" data-add-tracking="true" href=""><em>Wells Fargo Profits Rise, Defying JPMorgan Loss</em></a>]

Pharmacyclics (PCYC) was upgraded at Goldman Sachs to buy from neutral. $170 price target. ibruttinib could generate $7.5 billion of peak annual sales, Goldman said.

Premier Exhibitions (PRXI) was downgraded to sell at TheStreet Ratings.

Sonoco (SON) was downgraded at Goldman Sachs to sell from neutral. Company will likely grow slower than its peers over the next few quarters, Goldman said.

Stock Comments / EPS Changes

Calpine (CPN) estimates, price target were reduced at UBS. Estimates were reduced through 2014. Company lowered its guidance, UBS said. Buy rating and new $22 price target.

Lowe's (LOW) estimates, target upped at Credit Suisse. Estimates were boosted through 2015. Higher comp sales are driving gross margin expansion. Outperform rating and new $55 price target, Credit Suisse said.

Methanex (MEOH) estimates, price target were raised at UBS. Shares are now seen reaching $59. Estimates were also increased, as the company is seeing higher reference pricing, UBS said. Buy rating.

[Read: <a target="blank" data-add-tracking="true" href=""><em>Here's Where Your Neighbors Like to Have Sex</em></a>]

Micron (MU) estimates were increased at Jefferies. Elpida and DRAM ASPs contributing to income and gross margin, Jefferies said. Buy rating and $30 price target.

Micron estimates, price target were increased at UBS. DRAM pricing is moving higher, UBS said. Buy rating and new $23 price target.

>To submit a news tip, email:

Follow TheStreet on Twitter and become a fan on Facebook.
This article was written by a staff member of TheStreet.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AIZ $84.59 0.00%
GLW $18.89 0.00%
JNJ $112.48 0.00%
LLY $76.46 0.00%
MRK $55.74 0.00%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs